



GCRI Annual Report 2023-24

Q3. ONGOING INTRAMURAL AND EXTRAMURAL RESEARCH PROJECTS APRIL 2023-MARCH 2024

No.	Name of PI	Project Title	Funded by
Community Oncology & Medical Records			
1	Dr Shashank Pandya	Rural cancer registry-Ahmedabad District	National Centre for Disease Informatics and Research, ICMR, Bengaluru
2	Dr Shashank Pandya	Population based cancer registry-Ahmedabad urban agglomeration area	National Centre for Disease Informatics and Research, ICMR, Bengaluru
3	Dr Shashank Pandya	Hospital Based Cancer Registry (HBCRs) and patterns of care and survival studies on cancer breast, cancer cervix and head and neck cancers	National Centre for Disease Informatics and Research, ICMR, Bengaluru
4	Dr Bijal Patel Dr Anand Shah	Implementation plan for extended follow-up of the participants of IARC-Indian HPV vaccination study to evaluate the effectiveness of one, two and three doses of quadrivalent HPV vaccine in preventing cervical neoplasias	International Agency for Research on Cancer, Lyon, France
Collaborative Projects-Cancer Biology and Oncopathology Departments			
5	Dr Jahnvi Gandhi Dr Kruti Rajvik	Detection of ALKI, ROS-1, PDL1 using immunohistochemistry in non-small cell carcinoma of lung	GCS/GCRI
6	Dr Priti Trivedi Dr Jahnvi Gandhi Dr Kruti Rajvik	PDL-1 (SP-22C3) expression using immunohistochemistry in triple negative breast cancer	GCS/GCRI
7	Dr Priti Trivedi Dr Kruti Rajvik	Histological and molecular subtyping of medulloblastoma using immunohistochemical markers and its prognostic significance-Completed	GCS/GCRI
Cytogenetics			
8	Dr Pina Trivedi	Identification of oligodendroglia specific chromosomal changes 1p36/19q13.3 co-deletion by FISH analysis	GCS/GCRI
9	Dr Pina Trivedi	Assessment of MYC and BCL2 and/or BCL6 rearrangements in high-grade B-cell lymphoma	GCS/GCRI
10	Dr Dharmesh Patel	Cytogenetic exploration of Ewing Sarcoma with emphasis on rearrangement of EWSR1 gene	GCS/GCRI
Gynaecological Oncology			
11	Dr Bijal Patel	Prognostic evaluation of human epididymis protein 4 (HE4) in carcinoma cervix	GCS/GCRI



GCRI Annual Report 2023-24

No.	Name of PI	Project Title	Funded by
Immunohematology			
12	Dr Kruti Rajvik	To study microsatellite instability (MSI) in endometrial carcinoma patients by next generation sequencing	GCS/GCRI
13	Dr Birva Raiya	Detection of minimal residual disease in acute myeloid leukemia	GCS/GCRI
14	Dr Hemangini Vora	Development of miRNA profiling based signature of potential clinical relevance in triple negative breast cancer-Completed	GSBTM
Medical and Paediatric Oncology			
15	Dr Shashank Pandya	A phase III randomized controlled trial of single injection depot progesterone prior to surgery in women with high risk operable breast cancer	Tata Memorial Centre
16	Dr Shashank Pandya	Randomized controlled trial to assess blockade of voltage gated sodium channels during surgery in operable breast cancer	Tata Memorial Centre
17	Dr Harsha Panchal	Reditux TM registry to compare effectiveness, safety, and resource utilization of Reditux TM versus the reference medicinal product to treat diffuse large B cell lymphoma and chronic lymphocytic leukemia in routine clinical practice	Dr Reddy's Laboratory
18	Dr Harsha Panchal	Protocol no 0063-17'-A global multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere [®] (Docetaxel Injection Concentrate) in triple negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy	Lambda Therapeutic Research Ltd.
19	Dr Harsha Panchal	A randomized, double-blind, placebo-controlled phase III study of Darolutamide in addition to Androgen Deprivation Therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC)	Labcorp Drug Development India Pvt. Ltd.
20	Dr Harsha Panchal	A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant Giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer	PPD Pharmaceutical
21	Dr Harsha Panchal	A prospective, multicenter, non-interventional, observational, real-world study to evaluate the safety, adherence to therapy, and effectiveness of a T-DMI Antibody-Drug Conjugate Biosimilar in Indian patients with HER2-positive early breast cancer	BioQuest Solutions Pvt. Ltd.



GCRI Annual Report 2023-24

No.	Name of PI	Project Title	Funded by
22	Dr Sonia Parikh	A multicenter, open-label, randomized, phase III clinical trial to evaluate efficacy and safety of PF-114 versus Imatinib at 600 or 800 mg daily in adult patients with Philadelphia Chromosome positive (Ph+) Chronic Myeloid Leukemia (CML) in the chronic phase (CP) resistant to Imatinib at daily doses of 400 or 600 mg.	Edenwell Therapeutic
23	Dr Sonia Parikh	A prospective, multicenter, open-label, phase IV, interventional study to assess the safety and efficacy of Capmatinib in Indian patients with Mesenchymal-Epithelial Transition (MET) exon 14 Skipping mutation positive metastatic non-small cell lung cancer (NSCLC)	Siro Clinpharm
24	Dr Kajal Shah	Randomized, double-blind parallel group, phase III study to compare the efficacy, safety and immunogenicity of proposed Rituximab biosimilar (DRL_RI) with MabThera® in subjects with previously untreated, stage II-IV Cluster of Differentiation (CD) 20-positive, low tumor burden follicular lymphoma	Parexel International
25	Dr Kajal Shah	A phase IV, prospective, multicenter, open-label, non-comparative, interventional study to assess the safety of Alpelisib plus Fulvestrant, in men and postmenopausal women with HR positive, HER2-negative, advanced breast cancer (aBC) with a PIK3CA mutation whose disease has progressed on or after endocrine based treatment	Siro Clinpharm
26	Dr Maharshi Trivedi	A randomized, active-controlled, multicenter, open label, two arm study to assess safety, efficacy, pharmacodynamics, and pharmacokinetics with Pegfilgrastim PFS of Intas Pharmaceutical Limited compared with Neupogen® injection in paediatric patients under 6 years of age with Rhabdomyosarcoma or Wilms' tumor on Myelosuppressive chemotherapy regimen (Completed)	Lambda Therapeutic Research Ltd.
27	Dr Keval Patel	An open label, multicenter, non-randomized, dose-escalation, phase I study to evaluate safety and efficacy of intravesical SN-38 lipid suspension in patients with non-muscle invasive bladder cancer	Lambda Therapeutic Research Ltd.
Molecular Diagnostics and Research Lab-I			
28	Dr Trupti Trivedi	Establishment and validation of custom targeted gene panel for diffuse glioma patients-A next generation sequencing approach	GSBTM
29	Dr Trupti Trivedi	Exploring clinical significance of autophagy regulating genes in patients with glioma tumors	GCS/GCRI



GCRI Annual Report 2023-24

No.	Name of PI	Project Title	Funded by
30	Dr Trupti Trivedi	Using targeted next generation sequencing panel identification of molecular alterations of TERT, CDKN2A/B, FGFR1, PDGFRA and NF1 genes useful for classification of glioma tumors	GCS/GCRI
31	Dr Trupti Trivedi	Exploring significance of STAT3 signaling pathway in IDH wild type glioma patients-Completed	GCS/GCRI
32	Dr Trupti Trivedi	Elucidating clinical impact of Notch signaling pathway for medulloblastoma patients-Completed	GCS/GCRI
Molecular Diagnostics and Research Lab-II			
33	Dr Jayendrakumar Patel	Analysis of mutation profile in BCR-ABL 1 negative myeloproliferative neoplasm using next generation sequencing	GCS/GCRI
34	Dr Jayendrakumar Patel	Evaluation of association of p16 expression with presence of HPV DNA in oropharyngeal cancer patients	GCS/GCRI
35	Dr Toral Mandalia	Impact of normalized copy number (NCN) and normalized copy number on the international scale (IS-NCN) of major BCR-ABL transcripts on prognosis in CML patients	GCS/GCRI
36	Dr Toral Mandalia	Significance of molecules associated with cancer stemness in epithelial ovarian cancer	GCRI
37	Dr Toral Mandalia Dr Kinjal Gajjar Dr Hemangini Vora	HLA typing by next generation sequencing	GCRI
37	Dr Kinjal Gajjar	A comparative study of PCR/RFLP and real time PCR techniques for detection of FLT3 mutation in acute myeloid leukemia patients	GCS/GCRI
38	Dr Jayendrakumar Patel	Clinical Significance of JAK2V617F mutation and its validation droplet digital PCR method for myeloproliferative diseases-Completed	GCS/GCRI
39	Dr Toral Mandalia	To explore the clinical value of molecular markers in epithelial ovarian cancer-A preliminary study-Completed	GCS/GCRI
40	Dr Kinjal Gajjar	Clinical significance of expression of inflammatory response genes and DNA repair genes in colorectal carcinoma-Completed	GCS/GCRI
Molecular Diagnostics and Research Lab-III			
41	Dr Franky Shah	Sequencing based exome profiling for identification of metastasis associated genes in hereditary breast and ovarian cancer	ICMR
42	Dr Franky Shah	A study of BRCA1/2 methylation in hereditary breast and ovarian cancer	GCRI
43	Dr Franky Shah	Identification of BRCA associated miRNAs in hereditary breast and ovarian cancer	GCRI



GCRI Annual Report 2023-24

No.	Name of PI	Project Title	Funded by
44	Dr Franky Shah	Identification of miRNAs in breast cancer	GCRI
45	Dr Franky Shah	Evaluation of YAP/TAZ axis in breast cancer	GCRI
46	Dr Jigna Joshi	Salivary microRNAs and associated genomic profile for early prediction of oral cancer	DHR-ICMR
47	Ms Hunayna Bhavnagari	Identification of YAP-TAZ axis associated miRNAs in breast cancer	ICMR
48	Ms Bhoomi Tarapara	Integrated genomics approach to identify genetic alterations in hereditary breast and ovarian cancer patients	DHR-ICMR
Nuclear Medicine and PET CT			
49	Dr Ritesh Suthar	Role of Radioguided Surgery in Giant Cell Tumor, What extra it offer	GCRI

